Last reviewed · How we verify
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 Recombinant Adenovirus-5 Vector Vaccine, VRC-HIVADV014-00-VP Administered Alone or Administered as a Boost to a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA009-00-VP, in Uninfected Adult Volunteers in Uganda
The RV 156A clinical trial is evaluating an experimental HIV vaccine in people who are not infected with HIV. Participants in that study are randomly assigned to receive either the HIV vaccine or placebo. This study will enroll people who are participating in the RV 156 study. In this study, researchers will evaluate the safety of and immune response to a different experimental HIV vaccine in people who participated in the RV 156 study.
Details
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 18 |
| Start date | 2007-04 |
| Completion | 2009-10 |
Conditions
- HIV Infections
Interventions
- VRC-HIVADV014-00-VP Vaccine
Primary outcomes
- Local reactogenicity signs and symptoms — Measured through Day 336
- Systemic reactogenicity signs and symptoms — Measured through Day 336
- Laboratory measures of safety — Measured through Day 336
- Adverse and serious adverse experiences — Measured through Day 336
Countries
Uganda